Trevi Therapeutics completed a $162 million stock offering, extending its cash runway into 2030 to support ongoing development of Haduvio for chronic cough related to IPF, non-IPF ILD, and refractory chronic cough. The company plans to initiate multiple clinical trials in 2026, including Phase 3 trials for IPF-related chronic cough and Phase 2b trials for RCC and non-IPF ILD-related cough. With recent FDA alignment and a new European patent, Trevi is positioned to advance toward potential FDA approval. Financially, the company reported a net loss of $13.2 million for Q1 2026, with increased R&D and administrative expenses reflecting clinical progress.
A new patent application reveals a quantum AI project creating humanoid robots that can carry a person's 'digital DNA' to live alongside humans for centuries. This technology, part of a federally registered clinical trial, allows families to preserve...
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging the company may have provided misleading business information to investors in its stock-based mutual funds. Investors who purchased Pu...
CoreWeave secured a $35 billion deal with Meta, making Meta one of its largest customers through 2032. Despite this significant partnership, CoreWeave's shares fell following news related to Meta's own cloud services. The drop suggests investor conce...
Celestia (TIA) is experiencing a 25% decline year-to-date and is about to undergo a major token unlock releasing around $124,000 worth of tokens in two days, which may increase selling pressure. Despite weak on-chain performance and low blockchain ac...
SL Green's 1185 Sixth Ave tower has signed two leases totaling nearly 57,000 square feet, raising occupancy to about 92%. Ryan Specialty LLC renewed and expanded its 29,166 square-foot lease, while Solil Management LLC signed a new 27,508 square-foot...
